Citadel Advisors’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $39.1M | Buy |
2,242,176
+1,440,886
| +180% | +$25.1M | 0.01% | 614 |
|
|
2025
Q1 | $10.1M | Sell |
801,290
-4,166
| -0.5% | -$52.4K | ﹤0.01% | 1241 |
|
|
2024
Q4 | $8.5M | Buy |
805,456
+552,957
| +219% | +$5.83M | ﹤0.01% | 1425 |
|
|
2024
Q3 | $3.66M | Buy |
252,499
+161,741
| +178% | +$2.35M | ﹤0.01% | 2010 |
|
|
2024
Q2 | $772K | Sell |
90,758
-21,307
| -19% | -$181K | ﹤0.01% | 3321 |
|
|
2024
Q1 | $1.15M | Buy |
112,065
+80,262
| +252% | +$820K | ﹤0.01% | 3051 |
|
|
2023
Q4 | $174K | Buy |
31,803
+20,265
| +176% | +$111K | ﹤0.01% | 4668 |
|
|
2023
Q3 | $43.6K | Sell |
11,538
-208,810
| -95% | -$789K | ﹤0.01% | 5116 |
|
|
2023
Q2 | $1.48M | Buy |
220,348
+175,572
| +392% | +$1.18M | ﹤0.01% | 2669 |
|
|
2023
Q1 | $291K | Buy |
44,776
+36,479
| +440% | +$237K | ﹤0.01% | 4321 |
|
|
2022
Q4 | $70.8K | Sell |
8,297
-89,173
| -91% | -$761K | ﹤0.01% | 5149 |
|
|
2022
Q3 | $515K | Sell |
97,470
-134,196
| -58% | -$709K | ﹤0.01% | 4052 |
|
|
2022
Q2 | $982K | Buy |
231,666
+36,510
| +19% | +$155K | ﹤0.01% | 3422 |
|
|
2022
Q1 | $685K | Buy |
195,156
+101,591
| +109% | +$357K | ﹤0.01% | 4115 |
|
|
2021
Q4 | $623K | Buy |
93,565
+19,073
| +26% | +$127K | ﹤0.01% | 4355 |
|
|
2021
Q3 | $743K | Buy |
74,492
+39,844
| +115% | +$397K | ﹤0.01% | 4106 |
|
|
2021
Q2 | $1.07M | Buy |
+34,648
| New | +$1.07M | ﹤0.01% | 3944 |
|
|
2021
Q1 | – | Sell |
-138,138
| Closed | -$6.4M | – | 6780 |
|
|
2020
Q4 | $6.4M | Buy |
+138,138
| New | +$6.4M | ﹤0.01% | 1567 |
|